St. Joseph Hospital of Orange last week enrolled the first patient in the Los Angeles/Orange County region as part of its participation in a landmark clinical study that is designed to eliminate treatment-resistant hypertension.
Medtronic Inc. is conducting the nationwide clinical trial, which is designed to assess the safety and effectiveness of a renal denervation treatment in patients with hypertension and a high systolic blood pressure. The study involves a controlled trial, SYMPLICITY HTN-3, and an investigational Symplicity renal denervation system on about 80 patients across the country. The goal is to reach 530 patients.
“This is one of the most anticipated clinical trials in years addressing an important public health issue,” said Dr. Mahmood K. Razavi, an interventional radiologist at St. Joseph Hospital who is an investigator on this study.
For patients with medically resistant hypertension, the minimally invasive renal denervation procedure has shown a 30-point reduction in blood pressure. The process uses a catheter-based method to regulate nerve outputs in kidney-connected arteries. In hypertension patients, the renal nerves are hyperactive, which contributes to organ damage and high blood pressure.
About 9 million of 76 million Americans receive no relief from available medicines for their hypertension. Like high blood pressure, hypertension can lead to heart disease, heart failure, kidney disease and stroke.
UCI surgeons implant tiny eye telescope for patients with macular degeneration
St. Joseph doctor honored by California home care association
St. Joseph rebrands in drive to focus on community health